| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
|
van den Bent, Martin J
|
|
|
22 |
6 |
p. 813-823
|
artikel
|
| 2 |
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma
|
Rizzo, Alessandro
|
|
|
22 |
6 |
p. e237
|
artikel
|
| 3 |
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma
|
Funada, Satoshi
|
|
|
22 |
6 |
p. e236
|
artikel
|
| 4 |
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma – Author's reply
|
Bellmunt, Joaquim
|
|
|
22 |
6 |
p. e238
|
artikel
|
| 5 |
Asian ethnic minorities: underserved in cancer care
|
The Lancet Oncology,
|
|
|
22 |
6 |
p. 737
|
artikel
|
| 6 |
Benefit of adjuvant, but not concurrent, temozolomide for IDH-mutant anaplastic astrocytoma
|
Sasaki, Hikaru
|
|
|
22 |
6 |
p. 743-744
|
artikel
|
| 7 |
Biden determined to “end cancer as we know it”
|
Gourd, Elizabeth
|
|
|
22 |
6 |
p. 759
|
artikel
|
| 8 |
Brachytherapy—a dose of pragmatism needed
|
The Lancet Oncology,
|
|
|
22 |
6 |
p. 737
|
artikel
|
| 9 |
BRCA2: a 25-year journey from gene identification to targeted cancer treatment
|
Grinda, Thomas
|
|
|
22 |
6 |
p. 763-764
|
artikel
|
| 10 |
Cancer and COVID-19 vaccines: a complex global picture
|
Yusuf, Aasim
|
|
|
22 |
6 |
p. 749-751
|
artikel
|
| 11 |
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
|
Stratigos, Alexander J
|
|
|
22 |
6 |
p. 848-857
|
artikel
|
| 12 |
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
|
Pérez-García, José Manuel
|
|
|
22 |
6 |
p. 858-871
|
artikel
|
| 13 |
Christian Ntizimira: prioritising palliative care across Africa
|
Wilkinson, Emma
|
|
|
22 |
6 |
p. 761
|
artikel
|
| 14 |
Conflicts of interest in tobacco industry-funded research
|
Burki, Talha Khan
|
|
|
22 |
6 |
p. 758
|
artikel
|
| 15 |
Correction to Lancet Oncol 2021; 22: 309–20
|
|
|
|
22 |
6 |
p. e239
|
artikel
|
| 16 |
Correction to Lancet Oncol 2021; 22: 581–83
|
|
|
|
22 |
6 |
p. e239
|
artikel
|
| 17 |
Correction to Lancet Oncol 2021; 22: 872–82
|
|
|
|
22 |
6 |
p. e239
|
artikel
|
| 18 |
Correction to Lancet Oncol 2021; 22: 678–89
|
|
|
|
22 |
6 |
p. e239
|
artikel
|
| 19 |
COVID-19 mRNA vaccine-related adenopathy mimicking metastatic melanoma
|
Prieto, Peter A
|
|
|
22 |
6 |
p. e281
|
artikel
|
| 20 |
COVID-19 vaccines in patients with cancer
|
Trapani, Dario
|
|
|
22 |
6 |
p. 738-739
|
artikel
|
| 21 |
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
|
Dimopoulos, Meletios A
|
|
|
22 |
6 |
p. 801-812
|
artikel
|
| 22 |
Difficulties accessing cancer care in the Gaza Strip
|
Das, Manjulika
|
|
|
22 |
6 |
p. 757
|
artikel
|
| 23 |
Efforts to improve radiation oncology collaboration worldwide
|
Kassick, Megan
|
|
|
22 |
6 |
p. 751-753
|
artikel
|
| 24 |
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
|
Yu, Evan Y
|
|
|
22 |
6 |
p. 872-882
|
artikel
|
| 25 |
Enfortumab vedotin for cisplatin-ineligible urothelial cancer
|
Pignot, Geraldine
|
|
|
22 |
6 |
p. 748-749
|
artikel
|
| 26 |
Facing inadequacies: cultivating compassion from past failures
|
Khan, Adeel M
|
|
|
22 |
6 |
p. 762-763
|
artikel
|
| 27 |
Higher fatality from COVID-19 in patients with cancer in the UK than in Europe
|
Geraldes, Flávia Oliveira
|
|
|
22 |
6 |
p. 755
|
artikel
|
| 28 |
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
|
Pires da Silva, Ines
|
|
|
22 |
6 |
p. 836-847
|
artikel
|
| 29 |
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
|
Caimi, Paolo F
|
|
|
22 |
6 |
p. 790-800
|
artikel
|
| 30 |
Medical imaging and nuclear medicine: points to note
|
Jackson, Michael Robert
|
|
|
22 |
6 |
p. e225
|
artikel
|
| 31 |
Medical imaging and nuclear medicine: points to note
|
Eala, Michelle Ann B
|
|
|
22 |
6 |
p. e226
|
artikel
|
| 32 |
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
|
Altorki, Nasser K
|
|
|
22 |
6 |
p. 824-835
|
artikel
|
| 33 |
Pembrolizumab for relapsed or refractory Hodgkin lymphoma
|
Pulsoni, Alessandro
|
|
|
22 |
6 |
p. e234
|
artikel
|
| 34 |
Pembrolizumab for relapsed or refractory Hodgkin lymphoma – Author's reply
|
Kuruvilla, John
|
|
|
22 |
6 |
p. e235
|
artikel
|
| 35 |
Pembrolizumab monotherapy in advanced triple-negative breast cancer
|
Ganguly, Shuvadeep
|
|
|
22 |
6 |
p. e224
|
artikel
|
| 36 |
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
|
Sacco, Assuntina G
|
|
|
22 |
6 |
p. 883-892
|
artikel
|
| 37 |
Petition to ban nicotine pouches in Kenya
|
Burki, Talha Khan
|
|
|
22 |
6 |
p. 756
|
artikel
|
| 38 |
Prostate ultra-radical radiotherapy: reinventing the wheel
|
Sundar, Santhanam
|
|
|
22 |
6 |
p. e223
|
artikel
|
| 39 |
Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma
|
Tringale, Kathryn R
|
|
|
22 |
6 |
p. e218
|
artikel
|
| 40 |
Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma
|
Chua, Melvin L K
|
|
|
22 |
6 |
p. e217
|
artikel
|
| 41 |
Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma – Authors' reply
|
Liu, You-Ping
|
|
|
22 |
6 |
p. e219
|
artikel
|
| 42 |
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|
Monin, Leticia
|
|
|
22 |
6 |
p. 765-778
|
artikel
|
| 43 |
Secondary cytoreduction for relapsed ovarian cancer
|
Garg, Pankaj Kumar
|
|
|
22 |
6 |
p. e230
|
artikel
|
| 44 |
Secondary cytoreduction for relapsed ovarian cancer
|
Carneiro, Vandré Cabral Gomes
|
|
|
22 |
6 |
p. e231
|
artikel
|
| 45 |
Secondary cytoreduction for relapsed ovarian cancer
|
Iannantuono, Giovanni Maria
|
|
|
22 |
6 |
p. e232
|
artikel
|
| 46 |
Secondary cytoreduction for relapsed ovarian cancer – Authors' reply
|
Chen, Yulian
|
|
|
22 |
6 |
p. e233
|
artikel
|
| 47 |
Second-line immunotherapy in patients with metastatic melanoma
|
Wong, Annie
|
|
|
22 |
6 |
p. 746-748
|
artikel
|
| 48 |
The definition of pregnancy-associated breast cancer is outdated and should no longer be used
|
Amant, Frédéric
|
|
|
22 |
6 |
p. 753-754
|
artikel
|
| 49 |
The effect of non-AIDS-defining cancers on people living with HIV
|
Chiao, Elizabeth Y
|
|
|
22 |
6 |
p. e240-e253
|
artikel
|
| 50 |
The era of CD19-directed therapy in diffuse large B-cell lymphoma
|
Maddocks, Kami
|
|
|
22 |
6 |
p. 741-742
|
artikel
|
| 51 |
8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation
|
Groll, Andreas H
|
|
|
22 |
6 |
p. e254-e269
|
artikel
|
| 52 |
8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation
|
Lehrnbecher, Thomas
|
|
|
22 |
6 |
p. e270-e280
|
artikel
|
| 53 |
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
|
Siena, Salvatore
|
|
|
22 |
6 |
p. 779-789
|
artikel
|
| 54 |
Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer
|
Chau, Ian
|
|
|
22 |
6 |
p. 739-741
|
artikel
|
| 55 |
Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer
|
Levy, Antonin
|
|
|
22 |
6 |
p. e220
|
artikel
|
| 56 |
Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer
|
Xie, Li
|
|
|
22 |
6 |
p. e221
|
artikel
|
| 57 |
Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer – Authors' reply
|
Grønberg, Bjørn H
|
|
|
22 |
6 |
p. e222
|
artikel
|
| 58 |
Unresolved questions regarding the promise of the TPEx regimen
|
Kosaka, Makoto
|
|
|
22 |
6 |
p. e227
|
artikel
|
| 59 |
Unresolved questions regarding the promise of the TPEx regimen – Authors' reply
|
Guigay, Joël
|
|
|
22 |
6 |
p. e228-e229
|
artikel
|
| 60 |
WHO publishes framework for safe and affordable surgery in Western Pacific countries
|
Wilkinson, Emma
|
|
|
22 |
6 |
p. 760
|
artikel
|
| 61 |
Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?
|
Sepesi, Boris
|
|
|
22 |
6 |
p. 744-746
|
artikel
|
Tijdschrift beschrijving